Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00615056 · ClinicalTrials.gov registry record · Phase 2
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
NCT00615056 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 171 participants.
The verdict
NCT00615056, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
Study Summary
The study is designed to demonstrate that the combination of AG-013736 with either FOLFIRI or FOLFOX is superior to FOLFIRI or FOLFOX in combination with bevacizumab (Avastin) in delaying tumor progression in the second-line treatment of patients with metastatic colorectal cancer after failure of an irinotecan or oxaliplatin-containing first-line regimen.
Interventions
- DRUG AG-013736 (axitinib)
- DRUG Bevacizumab (avastin)
- DRUG FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])
- DRUG FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00615056
The ClinicalTrials.gov registry entry for NCT00615056 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which AG-013736 (axitinib) is the first listed.
NCT00615056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00615056 about?
NCT00615056 is a clinical study titled "A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen". The study is designed to demonstrate that the combination of AG-013736 with either FOLFIRI or FOLFOX is superior to FOLFIRI or FOLFOX in combination with bevacizumab (Avastin) in delaying tumor progression in the second-line treatment of patients with metastatic colorectal cancer after failure of an...
What is the current status of trial NCT00615056?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2008-03. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00615056?
The interventions under investigation include: AG-013736 (axitinib) (DRUG), Bevacizumab (avastin) (DRUG), FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]) (DRUG), FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]) (DRUG).
Who is sponsoring clinical trial NCT00615056?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.